![]() |
|
|
Vol. 30, Issue 12, 1329-1336, December 2002
Department of Biochemistry and Molecular Pharmacology, University
of Massachusetts Medical School, Worcester, Massachusetts
Methoxychlor, a currently used pesticide that in mammals elicits
proestrogenic/estrogenic activity and reproductive toxicity, has been
classified as a prototype endocrine disruptor. Methoxychlor is
prochiral, and its metabolites
1,1,1-trichloro-2-(4-hydroxyphenyl)-2-(4-methoxyphenyl)ethane (mono-OH-M); 1,1,1-trichloro- 2-(4-methoxyphenyl)-2-(3,
4-dihydroxyphenyl)ethane (catechol-M); and
1,1,1-trichloro-2-(4-hydroxyphenyl)-2-(3, 4-dihydroxyphenyl)ethane (tris-OH-M) are chiral; whereas 1,1,1-trichloro-2,
2-bis(4-hydroxyphenyl)ethane (bis-OH-M) is achiral. These metabolites
are formed during methoxychlor incubation with liver microsomes or
recombinant cytochrome P450s (rP450s). Since
methoxychlor-metabolite enantiomers may have different estrogenic/antiestrogenic/antiandrogenic activities than corresponding racemates, the possibility that P450s preferentially generate or use
R or S enantiomers, was examined. Indeed,
rCYP1A2 and r2A6 mono-demethylated methoxychlor primarily into
(R)-mono-OH-M at 91 and 75%, respectively, whereas
rCYP1A1, 2B6, 2C8, 2C9, 2C19, and 2D6 formed the
(S)-enantiomer at 69, 66, 75, 95, 96, and 80%, respectively. However, rCYP3A4, 3A5, and 2B1(rat) weakly demethylated methoxychlor without enantioselectivity. Human liver microsomes generated (S)-mono-OH-M (77-87%), suggesting that
CYP1A2 and 2A6 display only minor catalytic contribution. P450
inhibitors demonstrated that CYP2C9 and possibly 2C19 are major hepatic
catalysts forming (S)-mono-OH-M, and CYP1A2 is primarily
involved in forming the (R)-mono-OH-M. Demethylation
rate of (S)-mono-OH-M versus
(R)-mono-OH-M forming achiral bis-OH-M by rCYP1A2 was
97/3, compared with 15/85 and 17/83 for rCYP2C9 and 2C19, respectively,
indicating opposite substrate enantioselectivity of rCYP1A2 versus 2C9
and 2C19. Also, rCYP1A2 preferentially O-demethylated
(R)-catechol-M into (R)-tris-OH-M (at
80%), contrasting r2C9 and r2C19 that yielded
(S)-tris-OH-M at 80 and 77%, respectively.
Ortho-hydroxylation of mono-OH-M into catechol-M and
bis-OH-M into tris-OH-M was primarily by 3A4 and was not
enantioselective. In conclusion, enantiomeric abundance of methoxychlor
metabolites depends on the relative catalytic activity of the hepatic
P450 isoforms.
This article has been cited by other articles:
![]() |
B. A. Nyagode, M. O. James, and K. M. Kleinow Influence of Dietary Coexposure to Benzo(a)pyrene on the Biotransformation and Distribution of 14C-Methoxychlor in the Channel Catfish (Ictalurus punctatus) Toxicol. Sci., April 1, 2009; 108(2): 320 - 329. [Abstract] [Full Text] [PDF] |
||||
![]() |
H. Shen, K. M. Main, A.-M. Andersson, I. N. Damgaard, H. E. Virtanen, N. E. Skakkebaek, J. Toppari, and K.-W. Schramm Concentrations of persistent organochlorine compounds in human milk and placenta are higher in Denmark than in Finland Hum. Reprod., January 1, 2008; 23(1): 201 - 210. [Abstract] [Full Text] [PDF] |
||||
![]() |
J. C. Sacco and M. O. James SULFONATION OF ENVIRONMENTAL CHEMICALS AND THEIR METABOLITES IN THE POLAR BEAR (Ursus maritimus) Drug Metab. Dispos., September 1, 2005; 33(9): 1341 - 1348. [Abstract] [Full Text] [PDF] |
||||
![]() |
M.-F. Yueh, M. Kawahara, and J. Raucy HIGH VOLUME BIOASSAYS TO ASSESS CYP3A4-MEDIATED DRUG INTERACTIONS: INDUCTION AND INHIBITION IN A SINGLE CELL LINE Drug Metab. Dispos., January 1, 2005; 33(1): 38 - 48. [Abstract] [Full Text] [PDF] |
||||
![]() |
E. Hazai, P. V. Gagne, and D. Kupfer GLUCURONIDATION OF THE OXIDATIVE CYTOCHROME P450-MEDIATED PHENOLIC METABOLITES OF THE ENDOCRINE DISRUPTOR PESTICIDE: METHOXYCHLOR BY HUMAN HEPATIC UDP-GLUCURONOSYL TRANSFERASES Drug Metab. Dispos., July 1, 2004; 32(7): 742 - 751. [Abstract] [Full Text] [PDF] |
||||
![]() |
D. Bentrem, J. E. Fox, S. T. Pearce, H. Liu, S. Pappas, D. Kupfer, J. W. Zapf, and V. C. Jordan Distinct Molecular Conformations of the Estrogen Receptor {alpha} Complex Exploited by Environmental Estrogens Cancer Res., November 1, 2003; 63(21): 7490 - 7496. [Abstract] [Full Text] [PDF] |
||||